Experts to Discuss New Food Label Requirements at U.S. Food Labeling Seminar; Former FDA Official and Food Law Attorney Will Lead Discussion
Posted on: Wednesday, 10 May 2006, 15:04 CDT
The Food Institute and Olsson, Frank and Weeda, P.C. (OFW) will host a seminar on new food labeling regulations and policies on June 14 at the Marriott Newark International Airport Hotel. The seminar will feature panelists Elizabeth "Betty" Campbell, former Acting Director of the Office of Food Labeling at the U.S. Food and Drug Administration (FDA), and Robert Hahn, Esq., principle attorney at OFW. Ms. Campbell spent 35 years working at the FDA. Mr. Hahn specializes in food law.
The daylong seminar will review basic food labeling requirements and explain the changes in food labeling that became effective in 2006, including the new labeling requirements for trans fat and allergens. The seminar will also review new rules on health claims and country of origin labeling, and mock label reviews will be conducted. Possible future changes in food labeling being considered by FDA will also be discussed.
The full range of topics to be covered during the day-long discussion are:
-- Mandatory label information
-- Country of origin labeling
-- Trans fat labeling requirements
-- Allergen labeling requirements
-- Health and nutrient content claims
-- Structure/function claims
-- Descriptive claims including "Whole Grain,""Organic," and "Natural" claims
-- Common labeling mistakes
-- Warning and notice statements
The seminar will provide participants with a greater understanding of both longstanding and new food labeling requirements. Those interested in registering for the U.S. Food Labeling Seminar should visit http://www.foodinstitute.com/labelseminar06.cfm, call Sue Antista at (201) 791-5570, ext. 12, or fax (201) 791-5222, or send an e-mail to santista@foodinstitute.com
Source: Business Wire
Related Articles
- Traceability Institute Comments on Improving Food Safety System for Consumers at Food and Drug Administration (FDA) and Food Safety and Inspection Service (FSIS) Joint Public Meeting
- XDx's AlloMap(R) Gene Expression Test Cleared By U.S. Food and Drug Administration (FDA)
- Commenting on the U.S. Food and Drug Administration (FDA) Early Communication, Allergan Clarifies FDA's Inquiry Relates Primarily to High Dose Medical Uses of BOTOX(R), Rather Than BOTOX(R) Cosmetic for Aesthetic Use
- TyRx Pharma, Inc. Announces Food and Drug Administration (FDA) 510(K) Clearance of the AIGIS(Rx)(TM) Cardiac Rhythm Medical Device (CRMD) Anti-Bacterial Envelope, an Innovative Mesh Envelope Designed to Immobilize and Reduce Bacterial Infection of a Pacem
- Analyze Consumer Attitudes Towards Product Quality, Price, Premium Offerings, and Packaging in the American Private Label Foods Market
- Private-Label Food and Beverage Sales Set to Soar Past $56 Billion By 2011!
- TYZEKA(TM) (Telbivudine) Approved By U.S. Food and Drug Administration (FDA) As a New Treatment for Patients With Chronic Hepatitis B
- Chemical Heritage Foundation (CHF) and the Food and Drug Administration (FDA) Will Cosponsor FDA Centennial Conference at CHF on Tuesday, 16 May 2006
- U.S. Food and Drug Administration (FDA) Approves BARACLUDE(TM) (Entecavir) for Treatment of Chronic Hepatitis B
- The Level of Evidence for Permitting a Qualified Health Claim: FDA's Review of the Evidence for Selenium and Cancer and Vitamin E and Heart Disease1
 |
 |
User Comments (0)
RSS Feeds